Intuniv Drug Interactions

Links shared publicly online about this topic

INTUNIV (Guanfacine) drug information from MPR

empr.com — “INTUNIV (Guanfacine) drug information for ADD, ADHD {ADHD} from MPR including side effects, drug interactions, dosing, contraindications and warnings/precautions.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 13, 2011 at 4:19 am By:

eMPR MPR Medical Publisher

MPR News: INTUNIV: Indications: approved as adjunctive therapy. Children: adjunctive therapy dosing added. http://bit.ly/dTFdne

1 year ago...

Intuniv for ADHD: Metabolic Challenges

corepsychblog.com — “This post is the fifth, with four others, documenting Intuniv Overview, Dosing Details, Drug Interactions and Addiction Indications. Please review all of these posts for more informed use of IntunivView full resource at corepsychblog.com

  • View Related
  • Share

Most Recently Shared on February 1, 2010 at 11:01 am By:

drcharlesparkerEducator, Writer, NeuroscientistChild and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally." /> Dr Charles Parker Active Health Library, Doctor, Psychiatrist, and Physician

New post: Intuniv for ADHD: Metabolic Challenges http://goo.gl/fb/oOAJ

2 years ago...

Intuniv for ADHD: Metabolic Challenges

corepsychblog.com — “This post is the fifth, with four others, documenting Intuniv Overview, Dosing Details, Drug Interactions and Addiction Indications. Please review all of these posts for more informed use of IntunivView full resource at corepsychblog.com

  • View Related
  • Share

Most Recently Shared on February 4, 2010 at 9:50 am By:

drcharlesparkerEducator, Writer, NeuroscientistChild and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally." /> Dr Charles Parker Active Health Library, Doctor, Psychiatrist, and Physician

Many links on info re: Intuniv for ADHD: Metabolic Challenges http://bit.ly/d9jFyi including addiction, dosing, tenex #ADHD #neuroscience

2 years ago...

Intuniv for ADHD: Metabolic Challenges | CorePsych Blog

corepsychblog.com — “This post is the fifth, with four others, documenting Intuniv Overview, Dosing Details, Drug Interactions and Addiction Indications. Please review all of these posts for more informed use of IntunivView full resource at corepsychblog.com

  • View Related
  • Share

Most Recently Shared on October 31, 2010 at 5:22 pm By:

drcharlesparkerEducator, Writer, NeuroscientistChild and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally." /> Dr Charles Parker Active Health Library, Doctor, Psychiatrist, and Physician

Intuniv for ADHD: Metabolic Challenges - 63 Comments on dosing strategies http://bit.ly/ctGNUW #ADHD #medications #Medications

2 years ago...

Shire Announces FDA Approval of Once-Daily Intuniv (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17

drugs.com — “Intuniv (guanfacine) is used to treat Attention-Deficit/Hyperactivity Disorder in children and adolescents aged 6 to 17 years. Includes Intuniv side effects, interactions and indications.View full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on September 4, 2009 at 12:32 am By:

drugscom Drugs.com Health Site

FDA Approves Intuniv (guanfacine) for the Treatment of ADHD in Children and Adolescents - http://bit.ly/EObbC

3 years ago...

FDA Sends Shire Letter Over Intuniv Promotional Material - Drugs.com MedNews

drugs.com — “ROCKVILLE, Md., June 30, 2010 - The FDA today posted on its website a letter sent to Shire regarding a DTC Patient Starter Kit, which includes a Parents Guide,View full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on July 2, 2010 at 8:56 am By:

Health_CK Catherine K Health Advocate

FDA Sends Shire Letter Over Intuniv Promotional Material: ROCKVILLE, Md., June 30, 2010 - The FDA today poste... http://bit.ly/cGLlHy #adhd

2 years ago...

INTUNIV - Shire Files Suit Against Impax and Watson - Drugs.com MedNews

drugs.com — “DUBLIN and Shire plc (LSE SHP, NASDAQ SHPGY), the global specialty biopharmaceutical company, announces that its subsidiary Shire LLC has filed a lawsuit in theView full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on December 3, 2010 at 6:05 pm By:

Drugs_Devices Drugs and Devices OW OW Health

INTUNIV - Shire Files Suit Against Impax and Watson: DUBLIN and PHILADELPHIA, December 3, 2010/PRNewswire-... http://bit.ly/hxlE1j #drug

1 year ago...

Intuniv patient kit draws DDMAC untitled letter - Medical Marketing and Media

mmm-online.com — “Patient materials for Shire's ADHD drug Intuniv presented unsubstantiated effectiveness and superiority claims and downplayed important risk info, said the FDA's Division of Drug Marketing, Advertising and Communication.View full resource at mmm-online.com

  • View Related
  • Share

Most Recently Shared on July 1, 2010 at 1:42 am By:

PeterBrownPsy Peter H Brown Doctor and Psychologist

Intuniv patient kit draws DDMAC untitled letter http://bit.ly/bVxvTF #ADHD

2 years ago...

FDA expands approval of Shire's ADHD drug Intuniv - FirstWord

firstwordplus.com — “FDA expands approval of Shire's ADHD drug Intuniv - FirstWordView full resource at firstwordplus.com

  • View Related
  • Share

Most Recently Shared on February 28, 2011 at 4:37 pm By:

INTUNIV (Guanfacine) Extended Release Tablets For ADHD In Children And Adolescents Approved By FDA

medicalnewstoday.com — “Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV™ (View full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on September 5, 2009 at 12:05 pm By:

mnt_pediatrics MNT Pediatrics News Pediatrics and Health News

INTUNIV (Guanfacine) Extended Release Tablets For ADHD In Children And Adolescents Approved By FDA: Shire plc (L.. http://bit.ly/2IQcHz

3 years ago...

FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets For Use As Adjunctive Therapy To Stimulants For The Treatment Of ADHD

medicalnewstoday.com — “Shire plc, (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the use of once-daily INTUNIV® (guView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on March 1, 2011 at 8:33 pm By:

Health_CK Catherine K Health Advocate

FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets For Use As Adjunctive Therapy To Stimulants F... http://bit.ly/ePyJtA #adhd

1 year ago...

Child Behavior | Intuniv: ADHD Medication for Kids | Behavioral Coach

behavioralcoach.com — “Child Behavioral | This non-stimulant prescription drug is a treatment for attention deficit hyperactivity disorder (ADHD) children...View full resource at behavioralcoach.com

  • View Related
  • Share

Most Recently Shared on March 4, 2010 at 1:37 am By:

PeterBrownPsy Peter H Brown Doctor and Psychologist

Child Behavior | Intuniv: ADHD Medication for Kids | Behavioral Coach http://bit.ly/dsnU76

2 years ago...

Shire ADHD treatment Intuniv approved for use with a stimulant | Markets | Market News | Canadian Business Online

canadianbusiness.com — “Irish drugmaker Shire Plc. said Monday the U.S. Food and Drug Administration approved the use of attView full resource at canadianbusiness.com

  • View Related
  • Share

Most Recently Shared on March 1, 2011 at 7:04 am By:

PeterBrownPsy Peter H Brown Doctor and Psychologist

Shire ADHD treatment Intuniv approved for use with a stimulant http://bit.ly/hlBbwS #ADHD

1 year ago...

Investigational Data Presented for INTUNIV (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments - Drugs.com MedNews

drugs.com — “Shire plc (LSE SHP, Nasdaq SHPGY), the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV (guanfacine) Extended-View full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on October 28, 2010 at 4:15 pm By:

Drugs_Devices Drugs and Devices OW OW Health

Investigational Data Presented for INTUNIV (guanfacine) Extended-Release Tablets When Coadministered With Sti... http://bit.ly/9aEmxf #drug

2 years ago...

Medical News: FDA Extends ADHD Drug Indication - in Product Alert, Prescriptions from MedPage Today

medpagetoday.com — “WASHINGTON -- The FDA has approved the non-stimulant guanfacine (Intuniv) for the treatment of attention deficit hyperactivity disorder (ADHD) in combination with other therapies, including stimulantsView full resource at medpagetoday.com

  • View Related
  • Share

Most Recently Shared on March 1, 2011 at 7:04 am By:

The Top 3 resources shared on this topic. More resources.

Key stats and trends about this topic

Related Health Centers

Featuring the top 3 experts for this topic

  • eMPR

    MPR

    eMPR.com provides up-to-date, concise drug information at the point-of-care.

    View Profile

  • drcharlesparkerEducatorWriter, NeuroscientistChild and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally." />

    Dr Charles Parker

    Dr. Parker is an EducatorWriter, NeuroscientistChild and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally.

    View Profile

  • drcharlesparkerEducatorWriter, NeuroscientistChild and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally." />

    Dr Charles Parker

    Dr. Parker is an EducatorWriter, NeuroscientistChild and Adult psychiatrist, and is certified by the Nuclear Regulatory Commission for SPECT brain imaging. He specializes in advanced diagnostic and medical services for troubled children, adolescents and adults. His broad range of clinical experience from psychoanalysis to substance abuse, to psychopharmacology and SPECT neuroimaging, – and his experience with systems/functional medicine and biomedical assessments provides a comprehensive medical foundation for treatment interventions and recommendations. If you don't look, you can't see. At CorePsych mind/brain diagnosis evolves beyond the polemics of outdated categorical thinking driven by superficial labels. Virtual assessments available anywhere globally.

    View Profile

Advertisement

Share via Email

Share this WisdomCard with others by embedding on your site or blog.

300x260

425x300

560x390